GSK and XenoPort to Collaborate on Late-Stage Compound for RLS and Neuropathic Pain
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 81 (Table of Contents)
Published: 7 Mar-2007
DOI: 10.3833/pdr.v2007.i81.376 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
GlaxoSmithKline and XenoPort entered into an exclusive agreement to co-develop and commercialize XP13512 which is in Phase II trials for neuropathic pain and Phase III development for restless legs syndrome (RLS)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS